GlassScriptPhysician profile
Karina Lopez
NPI 1922872068
$779.25
in general payments reported to CMS, 2019-2025
14 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $14.82 · 2024: $587 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $146.39 | 2024 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $106.44 | 2024 | |
| Phathom Pharmaceuticals, INC. | $88.25 | 2024 | Voquezna |
| Pfizer INC. | $84.90 | 2024-2025 | |
| Dexcom, INC. | $77.32 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $54.16 | 2023-2024 | Omvoh, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $39.98 | 2025 | |
| Genzyme Corporation | $35.93 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $33.94 | 2024 | Airsupra |
| Qol Medical, LLC | $28.12 | 2024 | Sucraid |
| Sandoz INC. | $22.91 | 2024 | Hyrimoz |
| Ardelyx, INC. | $22.81 | 2024 | Ibsrela |
| Vivus LLC | $22.22 | 2024 | Pancreaze |
| Novo Nordisk INC | $15.88 | 2024 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karina Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.